Ghulam Rasool Mashori
Peoples University of Medical & Health Sciences for Women, Pakistan
Ghulam Rasool Mashori has completed his PhD at the age of 34 years from Faculty of Medicine, University Kebangsaan (National) Malaysia. He is the Director, Institute of Pharmaceutical Sciences and Peoples University of Medical & Health Sciences for Women Nawabshah (SBA), Sindh, Pakistan. He has published more than 20 papers in reputed journals. He has served with the Ministry of Health in various positions and also serving as an Editorial Board Member of repute Journals.
Treatment of hypertension has reduced the incidence of stroke, heart and renal failure. However the incidence of Coronary Heart Disease (CHD) is not reduced to the same degree. Many of the drugs advocated as first line drugs in step-wise therapy has been shown to cause carbohydrate intolerance, and it is an independent risk factor in the development of CHD. Since 1990’s individualized therapy in the treatment of hypertension has been advocated, whereby another class of antihypertensive drugs, such as calcium channel blockers (dihydropyridines) may be used as a first line therapy. Intracellular calcium plays important role in the excitation contraction coupling as well as the excitation-secretion coupling of hormones, including insulin. Absolute and relative lack of insulin can cause glucose intolerance. The purpose of the study was, to compare the effect of calcium channel blockers on insulin release from the rat isolated pancreas by perfusion technique, adapted from Loubatieries et al., 1972. The doses used were based on therapeutic peak plasma concentrations. Diazoxide has been used as positive control, i.e. known insulin suppressant drug. In the study Isradipine (10ng/ml) and Nicardipine (200ng/ml) showed significant suppression of the insulin release, this effect is dose dependent. Amlodipine (5ng/ml) significantly did not suppress the insulin release. Thus Amoldipine is found more useful drug amongst other calcium channel blocker. In conclusion different calcium channel blockers have varying effects on insulin release.